{
  "context": {
    "rules": [
      "Rule1: If the QC lab identifies contamination in the drug batch, then the company releases the drug batch to market.",
      "Rule2: If the QC lab identifies contamination in the drug batch, then the company does not release the drug batch to market.",
      "Rule3: Either the QC lab identifies contamination in the drug batch, or the research team completes safety protocols training, or the research team obtains authorization for the experimental drug.",
      "Rule4: If the regulatory agency initiates an investigation of the research facility, then the regulatory agency conducts an audit of the documentation.",
      "Rule5: If the regulatory agency conducts an audit of the documentation, then the regulatory agency issues a suspension of the research license.",
      "Rule6: Provided that the research team neither possesses GLP certification nor lacks approval for the clinical trial, then the research team receives a warning from the regulatory agency.",
      "Rule7: Under the condition that the research team neither possesses GLP certification nor lacks approval for the clinical trial, then the regulatory agency initiates an investigation of the research facility.",
      "Rule8: Should the research team fail to obtain authorization for the experimental drug, then the research team has approval for the clinical trial."
    ],
    "facts": [
      "Fact1: The research team does not possess GLP certification.",
      "Fact2: The research team does not receive a warning from the regulatory agency.",
      "Fact3: The research team does not complete safety protocols training.",
      "Fact4: The regulatory agency does not issue a suspension of the research license."
    ]
  },
  "question": "The research team obtains authorization for the experimental drug."
}